Spinal muscular atrophy (SMA) is the focus of a commentary by Jesy Nelson and Giles Lomax of SMA UK published in Nature Reviews Neurology on 28 July 2026. The authors note that disease-modifying therapies have transformed the overall prognosis for SMA, creating opportunities to change clinical trajectories when affected infants are identified and treated.
The article emphasizes that recent therapeutic developments have altered expectations for children with SMA. Although detailed clinical trial data and specific outcomes are not reproduced in this comment, the authors’ central point is that available treatments can be life-changing when delivered early in the disease course.
Nelson and Lomax highlight that, despite the availability of effective treatments, many children continue to experience substantial disability owing to delayed diagnosis. The commentary frames delayed identification as a key barrier that prevents timely access to therapies and supportive care, thereby undermining the potential benefits of medical advances for affected families.
The authors do not provide quantitative estimates within this piece of how delays translate into specific morbidity or functional loss. Instead, they make a policy-oriented argument that late diagnosis remains a major contributor to preventable disability in SMA.
The central recommendation of the commentary is that rapid implementation of newborn screening programmes for SMA is imperative. Nelson and Lomax argue that universal or broadly applied newborn screening is the missing step in current care pathways: identification at or shortly after birth would enable prompt initiation of disease-modifying therapies and supportive measures.
The authors present this recommendation as an urgent health-services priority. They assert that newborn screening would allow families and clinicians to act early, maximizing the benefit of available treatments and reducing the burden of disability that arises when diagnosis is delayed.
The article does not set out operational details for screening programmes, specific screening technologies, or implementation timelines. For those details, the authors point readers toward national screening documents and the organisations engaged in policy development and advocacy.
Nelson and Lomax reference a number of policy and advocacy resources to contextualize their call for newborn screening. These include documents and activities by the UK National Screening Committee and related Gov.UK materials on antenatal and newborn screening for SMA. The authors also cite the UK 10-year health plan as part of the broader policy environment.
The commentary points to active involvement from patient and advocacy organisations. SMA UK is named as an advocate for newborn screening, and the SMA NBS Alliance is referenced as a source tracking screening status internationally. The authors also note that national processes for assessing therapies continue—for example, evaluations relating to nusinersen and risdiplam are cited as in-development guidance by NICE.
Specific policy developments referenced include publication of SMA screening evidence documents by the UK National Screening Committee and announcements about new newborn screening initiatives in parts of the UK. The authors encourage engagement with these national and international resources for detailed evidence and implementation signals.
This comment was authored by Jesy Nelson and Giles Lomax of SMA UK and published in Nature Reviews Neurology on 28 July 2026. The authors state that they have no competing interests. The article is presented as a comment piece advocating for policy change—specifically rapid implementation of newborn screening for spinal muscular atrophy—and cites governmental and specialist references for readers seeking primary evidence or formal guidance.
Readers seeking the full text or underlying evidence documents are directed in the article to links for the UK National Screening Committee, Gov.UK recommendations on SMA screening, SMA UK advocacy pages, the SMA NBS Alliance status map, and other referenced sources. The commentary itself focuses on the policy imperative rather than presenting new empirical data.
References cited in the original commentary include governmental screening recommendations, a UK 10-year health plan, international clinical guidance on SMA diagnosis and management, national information resources (for example NINDS), NICE guidance in development, commentary on the human impact of slow decisions in SMA, and advocacy materials from SMA organisations. For full reference details readers should consult the published article and the referenced organisations’ documents.
Competing interests: the authors declare no competing interests.
Publication: Nelson J, Lomax G. Newborn screening is the missing step in spinal muscular atrophy care. Nat Rev Neurol (2026). DOI: 10.1038/s41582-026-01250-7. Published 28 July 2026.